Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
The firm also reported that full-year 2016 revenues grew 25 percent over 2015, driven in part by strong ePlex instrument sales.
It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.
The GenomeWeb Index stayed relatively flat in November, underperforming the Dow and Nasdaq for a second month in a row.
GenMark's CEO said that the firm continues to focus on growing the ePlex instrument's global reach and expanding its menu.
Encouraged by positive customer feedback from early installations, the firm is shifting its sales focus to the ePlex system and respiratory pathogen panel.
The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.
The investment bank said it has heard positive feedback from early adopters in Europe of GenMark's ePlex system and respiratory panel.
The company will soon submit its ePlex instrument and respiratory pathogen panel for US Food and Drug Administration clearance.
The GenomeWeb Index fell half a percent in June, underperforming the Dow Jones Industrial Average, but far outpacing the Nasdaq and Nasdaq Biotech Index.
In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.
Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.
Researchers are using gene editing to develop more robust livestock and crops, AFP reports.
Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.